Find and Pitch Jounalists, Get Your Story Covered

Tags: MDMA ecstasy PTSD therapy care continuum communication

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: To fight U.S. tariffs, Canada should suspend U.S. patents on medicines, one expert argues - about 1 month ago STAT+: Pharmalittle: We’re reading about Novo and GLP-1 compounding, Paxlovid and long Covid, and more - 3 months ago STAT+: Teva fined $503 million for disparaging a rival and using patents to thwart competition - 6 months ago STAT+: Pharmalittle: We’re reading about FTC scrutiny of a Novo deal, a Genentech reorganization, and more - 8 months ago STAT+: U.S. Patent Office software mistakes extend patent life for drugs and need to be fixed, researchers say - 9 months ago STAT+: A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down - 9 months ago STAT+: Biden administration appeals jury finding in battle over patents for HIV prevention pills - 9 months ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 10 months ago STAT+: Biden administration urged to license prostate cancer drug patents in a bid to lower its cost - about 1 year ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - about 1 year ago STAT+: FDA agrees to review a rare disease drug that its developer was about to give up on - about 1 year ago STAT+: Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - about 1 year ago STAT+: WTO proposal for Covid diagnostics and therapeutics waiver is abandoned - about 1 year ago STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about state moves on drug pricing, an asthma med for kids and more - about 1 year ago STAT+: A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived - about 1 year ago STAT+: Diabetes treatments have improperly listed patents that should be removed, analysis finds - about 1 year ago STAT+: Klobuchar urges drugmakers to remove patents FTC calls improper and inaccurate - about 1 year ago STAT+: New congressional bill would thwart patent thickets in order to speed generic drugs to market - over 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - over 1 year ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - over 1 year ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - over 1 year ago STAT+: Patent thickets and terminal disclaimers: How pharma blocks biosimilars from the marketplace - over 1 year ago STAT+: Pharmalittle: Curevac loses key patent in battle with BioNTech; Abernethy to step down as Verily CMO - over 1 year ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - over 1 year ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - over 1 year ago STAT+: Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns - over 1 year ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - over 1 year ago STAT+: Biden proposal targeting pharma patents spurs industry fears and consumer doubts - over 1 year ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - over 1 year ago STAT+: ‘Learning each other’s language’: FDA, patent office seek to work together to lower drug prices - over 1 year ago Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents - over 1 year ago STAT+: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough - over 1 year ago STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds - over 1 year ago STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin - over 1 year ago STAT+: FTC challenges several big drugmakers over inaccurate or improper patent listings - over 1 year ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - over 1 year ago STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India - over 1 year ago STAT+: Medicare is urged to consider Amgen patent maneuvers when negotiating the price for a drug - over 1 year ago STAT+: Pharmalittle: People with obesity harmed by exclusion from studies; Teva sues Colorado over ‘unconstitutional’ program - over 1 year ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - over 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - over 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago STAT+: How a cash-prize system that phases out patents may lower drug prices - over 1 year ago
2	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Merck is broadening its pipeline as Keytruda’s patent cliff looms - 3 months ago The first MASH drug could open the door for others — including GLP-1s - 5 months ago 3 FDA approval dates to watch in the year’s final push - 7 months ago 3 Big Pharma cancer drugs facing inflation penalties - 9 months ago BMS’ long-standing leukemia blockbuster stares down its first generic - 9 months ago FDA’s platform designation aims to ease R&D pain points - 10 months ago
3	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 3 months ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 3 months ago A biotech’s binary bet ends badly - 10 months ago
5	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	4 closely watched FDA approval dates in 2025 from J&J, Novo and more - 3 months ago Big Pharma earnings hang hope on the next generation of blockbusters - 6 months ago Will the IRA squash new drugs? Those worries are likely exaggerated, studies say. - 8 months ago The FDA pushes concrete plans to further diversity in clinical trials - 9 months ago Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake - about 1 year ago
6	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	3 closely watched drugs that failed in the clinic - 4 months ago Is anyone taking the world’s priciest drugs? - 8 months ago After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era - 11 months ago 3 recent FDA adcomm rejections — and why they matter - over 1 year ago
7	Shannon Firth MedPage Today Washington correspondent for MedPageToday. CUNYJschool pride. Healthcarejournalism	Experts Weigh Benefits of Drug Price Negotiation and Other Price-Curbing Strategies - 4 months ago Medical Schools Push Back on 'March-In' Rights Plan to Lower Drug Prices - about 1 year ago White House Says It Can Seize Certain Drug Patents to Lower Prices - over 1 year ago
8	Matthew Herper STAT News Writes at STAT. Biology's century. Undisclosed biologydatajournalism	STAT+: Merck says study of under-the-skin version of Keytruda, a bid to extend the drug’s sales, succeeded - 5 months ago
9	Torie Bosch STAT News Editor at STATNews. Hosts podcast. Pennsylvania opinionspodcasting	Opinion: STAT readers on hospital consolidation, patent system flaws, and asynchronous care - 6 months ago
10	N. Adam Brown MD MedPage Today Healthcare Strategist/Communicator. Washington, D.C. Healthcarestrategycommunication	Direct-to-Consumer Drugs: Big Pharma's Digital Health Play - 7 months ago

Journalists covering drug patents